ATE435024T1 - Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie - Google Patents

Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie

Info

Publication number
ATE435024T1
ATE435024T1 AT04730882T AT04730882T ATE435024T1 AT E435024 T1 ATE435024 T1 AT E435024T1 AT 04730882 T AT04730882 T AT 04730882T AT 04730882 T AT04730882 T AT 04730882T AT E435024 T1 ATE435024 T1 AT E435024T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
treatment
amyloid brain
brain angiopathy
Prior art date
Application number
AT04730882T
Other languages
English (en)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Application granted granted Critical
Publication of ATE435024T1 publication Critical patent/ATE435024T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
AT04730882T 2003-05-08 2004-05-03 Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie ATE435024T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Publications (1)

Publication Number Publication Date
ATE435024T1 true ATE435024T1 (de) 2009-07-15

Family

ID=32982086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730882T ATE435024T1 (de) 2003-05-08 2004-05-03 Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie

Country Status (19)

Country Link
US (6) US20090162362A1 (de)
EP (5) EP1623719B1 (de)
JP (5) JP2006525288A (de)
CN (2) CN101264326A (de)
AT (1) ATE435024T1 (de)
AU (2) AU2004237373A1 (de)
BR (1) BRPI0410684A (de)
CA (1) CA2524571C (de)
CY (1) CY1109454T1 (de)
DE (1) DE602004021797D1 (de)
DK (3) DK1623719T3 (de)
ES (6) ES2246177B1 (de)
IL (8) IL171651A (de)
MX (1) MXPA05010914A (de)
PL (3) PL1623719T3 (de)
PT (3) PT2075007E (de)
RU (2) RU2385161C2 (de)
SI (1) SI1623719T1 (de)
WO (1) WO2004098631A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7927594B2 (en) 2004-07-30 2011-04-19 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR101591223B1 (ko) 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
SI2238166T1 (sl) * 2007-10-05 2014-03-31 Genentech, Inc. Uporaba protitelesa proti amiloidu beta pri očesnih bolezni
EP2149380A1 (de) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Tierärztliche Immuntherapiezusammensetzung für altersbedingte kognitive Dysfunktion
EP2258398A1 (de) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin/Amyloidpeptid-Konjugate und deren Verwendungen
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
PT2510359E (pt) 2009-12-11 2015-12-02 Araclón Biotech S L Métodos e reagentes para a deteção melhorada de péptidos beta-amiloides
EP2542549B1 (de) 2010-03-03 2016-05-11 Probiodrug AG Glutaminylcyclase-hemmer
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2012009442A2 (en) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
MY164579A (en) * 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
DE69126304T2 (de) 1990-04-27 1997-09-04 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP3980833B2 (ja) * 1998-08-20 2007-09-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア βアミロイド斑及び神経原線維変化の標識方法
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070128191A1 (en) * 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (de) * 2002-06-06 2003-12-17 ABETA GmbH Diagnose von Alzheimer basiert auf dem hAbeta42:hAbeta40 Verhältnis
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
KR20050071564A (ko) * 2002-10-09 2005-07-07 리나트 뉴로사이언스 코퍼레이션 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물
RU2390350C2 (ru) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Активная иммунизация для создания антител к растворимому а-бета
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
EP2075007B9 (de) 2013-09-04
AU2011200170A1 (en) 2011-02-03
ES2329369T3 (es) 2009-11-25
IL207876A0 (en) 2011-07-31
IL207875A (en) 2013-02-28
IL207879A0 (en) 2011-07-31
PT2356996E (pt) 2013-08-23
IL207881A (en) 2013-02-28
IL171651A (en) 2011-11-30
JP2016065100A (ja) 2016-04-28
IL207880A0 (en) 2011-07-31
EP2356996B9 (de) 2013-08-28
ES2246105A1 (es) 2006-02-01
JP2014129389A (ja) 2014-07-10
MXPA05010914A (es) 2006-03-21
RU2005134351A (ru) 2006-04-27
CN101264326A (zh) 2008-09-17
ES2246178B1 (es) 2007-03-01
EP2305286A2 (de) 2011-04-06
IL207876A (en) 2013-03-24
EP2075007A2 (de) 2009-07-01
ES2423281T3 (es) 2013-09-19
IL207881A0 (en) 2011-07-31
IL207880A (en) 2013-02-28
EP2305286A3 (de) 2011-11-09
EP2356996B1 (de) 2013-06-26
PL2356996T3 (pl) 2013-09-30
IL207877A0 (en) 2011-07-31
BRPI0410684A (pt) 2006-06-20
CN1784240A (zh) 2006-06-07
RU2526155C2 (ru) 2014-08-20
JP2006525288A (ja) 2006-11-09
ES2246105B1 (es) 2007-03-01
US20170260234A1 (en) 2017-09-14
US20090162362A1 (en) 2009-06-25
WO2004098631A1 (es) 2004-11-18
DK2356996T5 (da) 2013-08-26
ES2246178A1 (es) 2006-02-01
EP2356996A1 (de) 2011-08-17
CA2524571A1 (en) 2004-11-18
AU2004237373A1 (en) 2004-11-18
RU2009148539A (ru) 2011-06-27
JP2012006967A (ja) 2012-01-12
IL207878A0 (en) 2011-07-31
IL207875A0 (en) 2011-07-31
DK2356996T3 (da) 2013-07-22
RU2385161C2 (ru) 2010-03-27
IL207879A (en) 2013-02-28
PL2075007T3 (pl) 2013-09-30
ES2423590T3 (es) 2013-09-23
CY1109454T1 (el) 2014-08-13
IL207877A (en) 2013-03-24
AU2011200170C1 (en) 2012-03-22
DE602004021797D1 (de) 2009-08-13
CA2524571C (en) 2017-01-10
EP1623719A1 (de) 2006-02-08
EP2082747A3 (de) 2010-01-13
US20200140488A1 (en) 2020-05-07
EP2075007B1 (de) 2013-05-22
EP2082747A2 (de) 2009-07-29
US20110262458A1 (en) 2011-10-27
EP2075007A3 (de) 2009-11-11
PL1623719T3 (pl) 2010-11-30
DK1623719T3 (da) 2009-11-09
SI1623719T1 (sl) 2009-12-31
DK2075007T3 (da) 2013-07-29
ES2246177A1 (es) 2006-02-01
EP1623719B1 (de) 2009-07-01
JP2018119011A (ja) 2018-08-02
IL207878A (en) 2013-02-28
ES2246177B1 (es) 2007-03-01
AU2011200170B2 (en) 2011-09-01
US20210214394A1 (en) 2021-07-15
PT2075007E (pt) 2013-08-23
PT1623719E (pt) 2009-10-08
US20140044725A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
ATE435024T1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE495755T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
ATE479442T1 (de) Beta-amyloidpeptid erkennende humanisierte antikörper
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60309514D1 (de) Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
DE60234031D1 (de) Mittel zur behandlung allergischer augenerkrankungen
DE60223674D1 (de) Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1623719

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1623719

Country of ref document: EP